Login / Signup

Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.

Menaka PaiNeill K J AdhikariMarlies OstermannDiane Heels-AnsdellJames D DouketisYoanna SkrobikIsmael QushmaqMaureen MeadeGordon GuyattWilliam GeertsMichael W WalshMark A CrowtherJan O FriedrichLisa BurryRinaldo BellomoNilton Brandão da SilvaRubens Costa FilhoMichael J CoxSuzana Alves SilvaDeborah J Cooknull null
Published in: PloS one (2018)
In critically ill patients with ESRD, or severe renal dysfunction, there was no significant difference in any VTE or major bleeding between UFH and dalteparin. Patients with severe renal dysfunction who received dalteparin had more proximal DVTs than those on UFH; this finding did not hold in patients with ESRD alone.
Keyphrases
  • venous thromboembolism
  • oxidative stress
  • phase iii
  • atrial fibrillation
  • direct oral anticoagulants
  • end stage renal disease
  • growth factor
  • phase ii
  • drug induced
  • open label